Daniela Savi

Daniela Savi

Auto-generated profile, based on publicly available information

Daniela Savi

Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, 00185, Rome, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
LKL. Kent
L. Kent
PRP. Reix
P. Reix
JIJ.A. Innes
J.A. Innes
SZS. Zielen
S. Zielen
MBM. Le Bourgeois
M. Le Bourgeois
KBK. De Boeck
K. De Boeck
The ECFS-CTN Standardisation Committee has undertaken this review of lung clearance index as part of the group's work on evaluation of clinical endpoints with regard to their use in multicentre clinical trials in CF. The aims were 1) to review the literature on reliability, validity and responsiveness of LCI in patients with CF, 2) to gain consensus of the group on feasibility of LCI and 3) to gain consensus on answers to key questions regarding the promotion of LCI to surrogate endpoint status. It was concluded that LCI has an attractive feasibility and clinimetric properties profile and is particularly indicated for multicentre trials in young children with CF and patients with early or mild CF lung disease. This is the first article to collate the literature in this manner and support the use of LCI in clinical trials in CF.

1 January 2010 in Respiratory Physiology & Neurobiology
Verified
Journal Article
Closed access
AHAlice Huertas
Alice Huertas
Ugo TestaUgo Testa
Ugo Testa
RRRoberta Riccioni
Roberta Riccioni
EPEleonora Petrucci
Eleonora Petrucci
VRViviana Riti
Viviana Riti
PPPaolo Palange
Paolo Palange

1 February 2018 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
TRThomas Radtke
Thomas Radtke
HHHelge Hebestreit
Helge Hebestreit
SGSabina Gallati
Sabina Gallati
JSJane E. Schneiderman
Jane E. Schneiderman
JBJulia Braun
Julia Braun
SKSusi Kriemler
Susi Kriemler
Rationale: Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human skeletal muscle cells. Variations of CFTR dysfunction among patients with cystic fibrosis may be an important determinant of maximal exercise capacity in cystic fibrosis. Previous studies on the relationship between CFTR genotype and maximal exercise capacity are scarce and contradictory. Objectives: This study was designed to explore factors influencing maximal exercise capacity, expressed as peak oxygen uptake (V. o2peak), with a specific focus on CFTR genotype in children and adults with cystic fibrosis. Methods: In an international, multicenter, cross-sectional study, we collected data on CFTR genotype and cardiopulmonary exercise tests in patients with cystic fibrosis who were ages 8 years and older. CFTR mutations were classified into functional classes I–V. Results: The final analysis included 726 patients (45% females; age range, 8–61 yr; forced expiratory volume in 1 s, 16 to 123% predicted) from 17 cystic fibrosis centers in North America, Europe, Australia, and Asia, all of whom had both valid maximal cardiopulmonary exercise tests and complete CFTR genotype data. Overall, patients exhibited exercise intolerance (V. o2peak, 77.3 ± 19.1% predicted), but values were comparable among different CFTR classes. We did not detect an association between CFTR genotype functional classes I–III and either V. o2peak (percent predicted) (adjusted β = −0.95; 95% CI, −4.18 to 2.29; P = 0.57) or maximum work rate (Wattmax) (adjusted β = −1.38; 95% CI, −5.04 to 2.27; P = 0.46) compared with classes IV–V. Those with at least one copy of a F508del-CFTR mutation and one copy of a class V mutation had a significantly lower V. o2peak (β = −8.24%; 95% CI, −14.53 to −2.99; P = 0.003) and lower Wattmax (adjusted β = −7.59%; 95% CI, −14.21 to −0.95; P = 0.025) than those with two copies of a class II mutation. On the basis of linear regression analysis adjusted for relevant confounders, lung function and body mass index were associated with V. o2peak. Conclusions: CFTR functional genotype class was not associated with maximal exercise capacity in patients with cystic fibrosis overall, but those with at least one copy of a F508del-CFTR mutation and a single class V mutation had lower maximal exercise capacity.

1 May 2019 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
DSDaniela Savi
Daniela Savi
SSStefano Schiavetto
Stefano Schiavetto
NSNicholas J. Simmonds
Nicholas J. Simmonds
DRDario Righelli
Dario Righelli
PPPaolo Palange
Paolo Palange

1 December 2015 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
DSDaniela Savi
Daniela Savi
NSNicholas Simmonds
Nicholas Simmonds
MPMarcello Di Paolo
Marcello Di Paolo
SQSerena Quattrucci
Serena Quattrucci
PPPaolo Palange
Paolo Palange
DBDiana Bilton
Diana Bilton
The aim of this study was to examine the relationship between pulmonary exacerbations and physical activity (PA) in adults with cystic fibrosis (CF). We grouped adults with CF according to their exacerbation status in the year before study enrolment: (1) 2 exacerbations/year. PA was assessed objectively by means of an accelerometer at the time of study enrolment. Patients with >2 exacerbations/year spent less time in PA; specifically, fewer activities of mild intensity [>3 metabolic equivalents (METs)], and lower active energy expenditure (P = 0.01 and P = 0.03, respectively). After correcting for relevant confounders, PA levels were not related to the exacerbation frequency in the preceding year. PA at moderate intensity (4.8–7.2 METs) or greater (>7.2 METs) was independently associated with gender and FEV1 % predicted (P = 0.007 and P = 0.04, respectively). Compared with men, women had reduced vigorous activities (P = 0.01) and active energy expenditure (P = 0.01). Adult CF patients with more pulmonary exacerbations in the preceding year have more advanced disease and are less active than their peers. PA was independently associated with gender and airflow obstruction. Gender differences in PA are evident in CF adults.

9 May 2015 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
DSDaniela Savi
Daniela Savi
MPMarcello Di Paolo
Marcello Di Paolo
NSNicholas Simmonds
Nicholas Simmonds
POPaolo Onorati
Paolo Onorati
MIMattia Internullo
Mattia Internullo
PPPaolo Palange
Paolo Palange
The best clinical practice to investigate aerobic fitness includes measurements obtained during cardiopulmonary exercise testing (CPET), however it remains an underutilised clinical measure in cystic fibrosis (CF). To investigate this further, different methods of quantifying exercise capacity in CF are required. The possibility that measuring physical activity (PA) by a portable accelerometer could be used to assess the CF aerobic state and could be added among the CPET surrogates has not been investigated. The aim of this study was to examine the relationship between PA and exercise fitness both at submaximal and maximal levels in clinically stable adults with CF. Thirty CF patients (FEV1 71 ± 19% predicted) and fifteen healthy controls undertook an incremental CPET on a cycle ergometer. CPET-related measurements included: oxygen uptake (V’O2), carbon dioxide production (V’CO2), ventilatory profile, heart rate (HR) and oxygen pulse (V’O2/HR) throughout exercise and at lactic threshold (LT) and peak. LT measures represent submaximal exercise related data. PA was assessed using the accelerometer SenseWear Pro3 Armband. Moderate (>4.8 metabolic equivalents (METS)) and moderate + vigorous (>7.2 METS) PA was related to V’O2 (p = 0.005 and p = 0.009, respectively) and work rate (p = 0.004 and p = 0.002, respectively) at LT. Moderate PA or greater was positively related to peak V’O2 (p = 0.005 and p = 0.003, respectively). Daily PA levels were similar in CF and healthy controls. Except for peak values, V’O2 profile and the V’O2 at LT were comparable between CF and healthy controls. In adult CF patients daily PA positively correlated with aerobic capacity. PA measurements are a valuable tool in the assessment of exercise performance in an adult CF population and could be used for interventional exercise trials to optimize exercise performance and health status. PA levels and parameters obtained at submaximal exercise are similar in CF and in healthy controls.